Skip to main content
$18.79 -$0.99 (-5.0%)

01:00 PM EST on 11/26/21

ACADIA Pharmaceuticals, Inc. (NASDAQ:ACAD)

CAPS Rating: 3 out of 5

The Company is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders.

Current Price $18.79 Mkt Cap $3.2B
Open $19.45 P/E Ratio 0.00
Prev. Close $18.79 Div. (Yield) $0.00 (0.0%)
Daily Range $18.58 - $19.90 Volume 890,763
52-Wk Range $15.68 - $57.34 Avg. Daily Vol. 1,222,471

Caps

How do you think NASDAQ:ACAD will perform against the market?

Add Stock to CAPS Watchlist

All Players

281 Outperform
71 Underperform
 

All-Star Players

24 Outperform
15 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:ACAD Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

MarkBiotech (< 20)
Submitted April 05, 2017

Nuplazid is the first drug approved for the treatment of PD psychosis. This market represents a 2-3B peak in sales. If Pimavanserin successfully expands its label to Alzheimer psychosis, Alzheimer agitation, schizo IRAT, then you have a company with… More

constructive (27.62)
Submitted March 03, 2017

This article does a good job of laying out the bear case: http://seekingalpha.com/article/4015176-acadias-nuplazid-blockbuster-drug-imaginedThe market may turn out to be smaller than expected, especially with the black box warning ("Side effects… More

Recent Community Commentary

Read the most recent pitches from players about ACAD.

Recs

0
Member Avatar pitbullsneedlove (27.75) Submitted: 8/15/2020 6:51:41 PM : Outperform Start Price: $39.85 NASDAQ:ACAD Score: -88.66

It’s already profitable and I see a lot of uses for its medicine.

Recs

0
Member Avatar NHWeston102 (76.61) Submitted: 5/2/2020 2:10:25 PM : Outperform Start Price: $47.37 NASDAQ:ACAD Score: -121.20

Leading dementia treatment candidates.

Recs

0
Member Avatar TMFAdriaCimino (22.36) Submitted: 2/20/2020 4:08:47 AM : Outperform Start Price: $45.52 NASDAQ:ACAD Score: -94.59

Nuplazid sales in Parkinson's disease psychosis are growing and trials in other indications are looking positive. If approved for additional indications, the drug can drive long-term sales.

Leaderboard

Find the members with the highest scoring picks in ACAD.

Score Leader

TrackLadenburg

TrackLadenburg (< 20) Score: +2,706.67

The Score Leader is the player with the highest score across all their picks in ACAD.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
jamrod02 51.41 12/20/2010 Outperform 5Y $0.77 +2,340.58% +268.24% +2,072.34 0 Comment
noobtery 58.28 10/28/2010 Outperform 5Y $0.83 +2,163.86% +286.14% +1,877.72 0 Comment
Hornet41 42.84 12/22/2010 Outperform 5Y $0.90 +1,987.55% +265.77% +1,721.77 0 Comment
Ruckwerts 26.52 12/1/2011 Outperform 3Y $0.93 +1,920.43% +267.85% +1,652.58 0 Comment
dsherid2 < 20 11/30/2011 Outperform 1Y $1.03 +1,724.45% +269.42% +1,455.03 0 Comment
Smog79 < 20 8/12/2010 Outperform 3W $1.04 +1,706.73% +322.59% +1,384.14 0 Comment
drmanand 45.66 7/14/2010 Outperform 1Y $1.11 +1,593.10% +319.88% +1,273.22 1 Comment
smallandmidcap 90.33 8/10/2010 Outperform 5Y $1.13 +1,562.83% +309.68% +1,253.15 0 Comment
dmkj50 < 20 10/27/2011 Outperform 5Y $1.17 +1,505.85% +258.77% +1,247.08 0 Comment
tappo3833 92.64 1/3/2011 Outperform 1Y $1.19 +1,478.99% +262.22% +1,216.77 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for ACAD.